Status:
COMPLETED
Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen
Lead Sponsor:
Duke University
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Chronic Hepatitis C
Organ Transplantation
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
Liver transplant subjects will be given Mycophenolate (MMF) and Tacrolimus in order to help prevent post-transplant rejection.
Detailed Description
Recurrent HCV in the liver allograft is becoming the leading indicator for retransplantation. Studies suggest that glucocorticord-based immunosuppression regimens hasten the onset and progression of r...
Eligibility Criteria
Inclusion
- adult patients who have received liver transplant
Exclusion
- pregnant women
- nursing women
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
February 1 2009
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00286871
Start Date
February 1 2006
End Date
February 1 2009
Last Update
September 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710